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Objective: Cetuximab (Erbitux
w) was approved for the treatment of metastatic colorectal
cancer in Japan in 2008. To verify information on the safety in practical use of cetuximab, we
conducted post-marketing surveillance in accordance with the conditions for approval.
Methods: All patients to be treated with cetuximab were enrolled by the central enrolment
method. Data on treatment status, and incidence and severity of adverse drug reactions were
collected. The target number of patients was 1800.
Results: A total of 2126 patients were enrolled from 637 institutions. Among 2006 patients
analysed, 93.2% received cetuximab as third-line or later treatment. The median duration of
treatment was 15.3 weeks, and 11.1% of patients received treatment for .48 weeks. The in-
cidence of adverse drug reactions was 89.6%, of which  grade 3 was 21.5%. The incidence
of infusion reactions was 5.7% (any grade), with 83.3% of them occurring at the ﬁrst adminis-
tration. The incidence of skin disorders was 83.7% (any grade), and the time to event varied
for each skin disorder. The incidence of interstitial lung diseases was 1.2% (any grade).
Diarrhoea and haematotoxicity scarcely occurred with cetuximab alone.
Conclusions: In this surveillance, the incidence and categories of adverse drug reactions
are not distinct from previous reports. Although most patients received cetuximab as third-line
or later treatment, treatment was maintained with a median duration of 15 weeks. Cetuximab
treatment in practical use is considered to be well tolerated and clinically useful in Japanese
patients with metastatic colorectal cancer.
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INTRODUCTION
Cetuximab (Erbitux
w) is a human/mouse chimeric monoclo-
nal immunoglobulin G1 antibody that targets the epidermal
growth factor receptor (EGFR) to inhibit its signalling and
shows anti-tumour effects by binding to EGFR competitively
with ligands (1,2). Cetuximab, administered alone or in com-
bination with irinotecan, showed efﬁcacy in the treatment of
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(CRC) who are refractory to irinotecan (3). Subsequent
studies conﬁrmed the efﬁcacy and safety of cetuximab alone
or in combination with chemotherapy (4,5). Moreover, it was
reported that KRAS status is a predictive marker of response
to cetuximab (6–8).
Based on these studies and a Japanese phase II study (9)
in which cetuximab was administered in combination with
irinotecan in 39 patients with EGFR-positive metastatic CRC
refractory to irinotecan, cetuximab was approved in Japan as
second-line and later treatment for EGFR-positive metastatic
CRC in July 2008.
In Japan, post-marketing surveillance (PMS) has been
introduced to verify the safety and the clinical efﬁcacy of
medicines in practical use, and practice standards of PMS
have been established under a ministerial order. As a condi-
tion of its approval, PMS of all patients receiving cetuximab
during a certain period was requested by the Ministry of
Health, Labour and Welfare.
In this report, treatment status and safety in the clinical
use of cetuximab are examined based on prospectively
aggregated PMS data.
PATIENTS AND METHODS
ENROLMENT
Following the launch of cetuximab on 19 September 2008,
all patients to be treated with cetuximab were enrolled in
advance using the central enrolment method. Patient infor-
mation, including gender, age and treatment line, was col-
lected from a company (Merck Serono Co., Ltd. and
Bristol-Myers K.K.) prepared enrolment sheet. The company
checked whether the patients met the following conditions
for proper use upon approval: positive EGFR, no history of
hypersensitivity to the components of the product, perform-
ance status (PS) 0–1, no interstitial lung diseases (ILDs) and
refractoriness or intolerance to previous chemotherapy.
To detect adverse drug reactions (ADRs) with an inci-
dence of 0.2% and a probability of at least 95%, and to com-
plete the enrolment within 1 year after launch, the target
number of patients was determined to be 1800.
TREATMENT
In accordance with the statement on the package insert, the
initial dose of cetuximab was administered at 400 mg/m
2
over 2 h followed by weekly infusions of 250 mg/m
2 over
1 h. As there were no data available on the efﬁcacy and
safety of cetuximab in combination with oxaliplatin-based
regimens at the beginning of the surveillance in Japan,
it was recommended to use irinotecan or FOLFIRI
(folinic acid, ﬂuorouracil and irinotecan) as a combination
chemotherapy.
To reduce the risk of infusion reactions (IRs), pre-
medication with antihistamines is recommended in the
‘precautions for use’ section on the package insert for cetux-
imab. Likewise, concomitant use of corticosteroid is also
suggested to reduce the risk of IRs.
MONITORING
The observation period was deﬁned as the time between the
ﬁrst administration and the last administration of cetuximab.
The case report forms including information of treatment
status and ADRs ﬁlled out by physicians were collected
three times (at Week 4, Week 8 and ﬁnal administration).
SAFETY EVALUATION
Severities of adverse events (AEs) were assessed mainly
according to the Common Terminology Criteria for Adverse
Events version 3.0 (CTCAE v3.0). As priority survey items,
the incidence and severity of IRs, skin disorders, ILDs, elec-
trolyte abnormalities including hypomagnesaemia, cardio-
toxicity, gastrointestinal disorders, thrombosis/embolism,
delayed wound healing and eye disorders (e.g. keratitis) were
surveyed. AEs that the physicians and the company deﬁned
as being related to cetuximab treatment were analysed
as ADRs.
STATISTICAL ANALYSIS
All analyses were performed using SAS (version 9.2; SAS
Institute, Inc., Cary, NC, USA). The incidences of ADRs,
the number of treatment and duration of treatment were com-
pared among patients characteristics and therapeutic factors
using the x
2 test, Fisher’s exact test, the Wilcoxon rank sum
test or the non-paired t-test. P , 0.05 was considered to rep-
resent a statistically signiﬁcant difference. The Kaplan–
Meier method was used to calculate the cumulative inci-
dence of ADRs.
RESULTS
PATIENT CHARACTERISTICS
Between 19 September 2008 and 5 January 2009, 2126
patients were enrolled from 637 institutions. Excluding 154
patients who did not receive cetuximab treatment, but in-
cluding 34 who were treated with cetuximab outside of the
enrolment condition, 2006 patients were included in the ana-
lysis. The cut-off date was set at 5 January 2010 (including
patients continuing treatment).
The patient characteristics are shown in Table 1.
The median age was 64 years (range, 18–87), the male/
female ratio was 1:0.6 and 93.2% of patients received cetux-
imab as third-line or later treatment (Table 1). In this surveil-
lance, KRAS testing was performed in 15%.
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n %
(A) Patient characteristics
Sex
Male 1234 61.5
Female 772 38.5
Age
,65 years 1032 51.4
 65 years 971 48.4
Unknown 3 0.2
Tumour site (including overlapping sites)
Colon 1235 61.6
Rectum 775 38.6
PS
0 1370 68.3
1 630 31.4
2 2 0.1
Unknown 4 0.2
Treatment line
Second line 133 6.6
Third line and later treatment 1869 93.2
Others 4 0.2
Previous chemotherapy
(2) 3 0.2
(þ) 2003 99.9
FOLFIRI 1510 75.3
FOLFOX 1854 92.4
5-FU/LV 370 18.4
Irinotecan 261 13.0
UFT/LV 337 16.8
Bevacizumab 923 46.0
Previous surgery
(2) 81 4.0
(þ) 1925 96.0
Previous radiation therapy
(2) 1650 82.3
(þ) 355 17.7
Unknown 1 0.0
EGFR-IHC
Positive 1974 98.4
Negative 29 1.4
Not tested 3 0.2
KRAS status
Wild 249 12.4
Mutant 53 2.6
Continued
Table 1. Continued
n %
Not tested 1691 84.3
Unknown 13 0.7
Comorbidity
(2) 1019 50.8
(þ) 974 48.6
Unknown 13 0.6
(B) Clinical use
No. of treatments
,4 253 12.6
4t o,16 900 44.9
16 to ,32 524 26.1
32 to ,48 255 12.7
 48 74 3.7
Duration of treatment
,4 weeks 276 13.8
4t o, 16 weeks 739 36.8
16 to ,32 weeks 489 24.4
32 to ,48 weeks 280 14.0
 48 weeks 222 11.1
Cumulative dose
,1500 mg/m
2 435 21.7
1500 to ,3000 mg/m
2 493 24.6
3000 to , 9000 mg/m
2 832 41.5
 9000 mg/m
2 236 11.8
Unknown 10 0.5
Combination chemotherapy
(2) 460 22.9
(þ) 1546 77.1
Irinotecan 1255 62.6
FOLFIRI 256 12.8
Others 35 1.7
Combination radiation therapy
(2) 1943 96.9
(þ) 59 2.9
Unknown 4 0.2
Pre-medication
a
No 14 0.7
Antihistamine alone 185 9.2
Corticosteroid alone 23 1.2
Antihistamine þ corticosteroid 1783 88.9
PS, performance status; 5-FU, 5-ﬂuorouracil; LV, leucovorin; UFT, tegafur-
uracil; EGFR, epidermal growth factor receptor; IHC, immunohistochemistry.
aExcluded unknown (one patient).
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In total, 77.1% of patients received cetuximab in combin-
ation with chemotherapy, and the rest received cetuximab
alone. Almost all patients (99.3%) received pre-medication,
and most of these (88.9%) were treated with both antihista-
mines and corticosteroids (Table 1).
The median duration of treatment was 15.3 weeks (range,
1–73.9), the median numbers of treatment was 13 (range,
1–61) and the median cumulative dose was 3255 mg/m
2
(range, 50.0–17680.9). A total of 11.1% of patients contin-
ued cetuximab treatment for .48 weeks (Table 1). The
number of treatment and the duration of treatment by patient
characteristics are shown in Fig. 1. Treatment duration did
not differ among treatment line. The number of treatment
was signiﬁcantly higher, and the duration of treatment was
signiﬁcantly longer in the patients with combination
chemotherapy, wild KRAS tumours and skin disorders
(P , 0.0001).
SAFETY
The overall incidence of ADRs (any grade) was 89.6% (n ¼
1797), and that of ADRs of  grade 3 was 21.5% (n ¼ 432)
(Table 2). Among patient characteristics affecting the inci-
dence of  grade 3 ADRs, signiﬁcant differences were
observed in the comorbidity (presence, 25.5% vs. none,
18.1%; P , 0.0001) and combination chemotherapy (pres-
ence, 23.2% vs. none, 15.9%; P ¼ 0.0006). There were no
signiﬁcant differences by age (,65 years, 21.4% vs.   65
years, 21.6%; P ¼ 0.91).
Incidences of the priority survey items are shown in
Table 2. IRs were observed in 5.7% of patients (n ¼ 114),
whereas IRs  grade 3 were observed in 1.1% (n ¼ 22).
Most IRs (83.3%; n ¼ 95), especially those of  grade 3 (20
out of 22) occurred at the ﬁrst administration of cetuximab
(Fig. 2). The median time to the onset of  grade 3 IRs was
10 min (range, 2 min to 8 h). Among the 22 patients with
IRs of  g r a d e3 ,2 1d e v e l o p e dI R sw i t h i n6 0m i na f t e rt h e
start of administration. There were no differences in the inci-
dence of IRs among pre-medication groups (data not shown).
Skin disorders were the most frequently observed ADRs,
accounting for 83.7% of patients (n ¼ 1679, any grade). In
the seven categories grouped by symptom, dermatitis acnei-
form/rash (n ¼ 1579, 78.7%) was observed most frequently,
followed by dry skin (n ¼ 442, 22.0%) and paronychia (n ¼
353, 17.6%). The cumulative incidence of each disorder over
time after the start of administration of cetuximab is shown
in Fig. 3. The median time to the onset of each skin disorder
was 15 days for dermatitis acneiform/rash, 30 days for dry
skin and 52 days for paronychia.
ILDs were observed in 1.2% of patients (n ¼ 24), and
ILDs  grade 3 were reported in 0.7% (n ¼ 15). The out-
comes included recovery in 2 patients, lower severity in 6
patients, non-recovery in 5 patients, death in 10 patients and
unknown in 1 patient. The median time to onset of ILDs was
101 days (range, 17–431), indicating no certain tendency in
time to onset of ILDs.
Electrolyte abnormalities (any grade, 11.5%;  grade 3,
1.2%) included hypomagnesaemia (10.8%), hypocalcaemia
(0.5%), hyperkalaemia (0.4%), hypokalaemia (0.3%), hypo-
natraemia (0.2%), hypochloraemia (0.1%) and hypophospha-
taemia (0.1%). The median time to onset of
Figure 1. Number and duration of treatment by patient characteristics. The bars show the median duration of the cetuximab treatment for each subgroup of
patients. *P , 0.0001 (the non-paired t-test).
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higher rate of hypomagnesaemia was observed in patients
undergoing long-term administration.
Cardiotoxicity was observed in 17 patients (0.9%) and
cardiotoxicity  grade 3 was reported in 0.2% (n ¼ 5).
Cardiotoxicity included myocardial infarction, cardiac failure,
right cardiac failure and coronary spastic angina. All ﬁve
patients with cardiotoxicity  grade 3 were treated with cetuxi-
mab plus irinotecan or FOLFIRI, and four patients died.
Other ADRs developed including diarrhoea (any grade,
15.1%;  grade 3 2.5%), leukopenia (4.3%; 2.0%) and neu-
tropenia (2.8%; 2.2%). Leukopenia and neutropenia did not
occur in the cetuximab alone group, and the incidence of
diarrhoea in this group was lower than that in the combin-
ation chemotherapy group (5.2 vs. 18.0%, P , 0.001)
(Fig. 4).
A total of 780 patients died during the surveillance period.
Of these, a causal relationship with cetuximab could not be
ruled out in 22 patients (1.1%). Of the 66 patients (3.3%)
who died within 30 days, a causal relationship with cetuxi-
mab could not be ruled out in seven patients (0.4%).
DISCUSSION
This report shows the results of a large-scale surveillance in
which all patients treated with cetuximab were collected pro-
spectively within a certain period after launch.
The incidence of ADRs in this surveillance (89.6%) was
similar to that (93.0%) reported in the MABEL study, in
which the efﬁcacy and safety of the combination with irino-
tecan were studied in 1147 patients with EGFR-positive
metastatic CRC refractory or intolerant to irinotecan (10),
and that (100%) reported in a Japanese phase II study (9).
Because IRs occurred frequently at the ﬁrst administration
of cetuximab and most of the severe reactions occurred
within 1 h after administration, careful observation during
the ﬁrst 1 h is therefore important in cetuximab treatment. It
was reported that the incidence of IRs was decreased by
administering antihistamine and corticosteroid as pre-
medication (11). Accordingly, the Japanese package insert
for cetuximab recommends pre-medication with an antihista-
mine (and corticosteroid), and 88.9% of patients received
both pre-medications in this surveillance. So, the incidence
Table 2. Incidence of adverse drug reactions (ADRs)
Any grade  Grade 3
n % n %
Overall incidence of ADRs 1797 89.6 432 21.5
Incidence of priority survey items
Infusion reactions 114 5.7 22 1.1
Skin disorders 1679 83.7 212 10.6
Interstitial lung diseases 24 1.2 15 0.7
Electrolyte abnormalities including
hypomagnesaemia
231 11.5 24 1.2
Cardiotoxicity 17 0.9 5 0.2
Gastrointestinal disorders 464 23.1 77 3.8
Thrombosis/embolism 11 0.6 8 0.4
Delayed wound healing 5 0.3 1 0.05
Eye disorders 53 2.6 1 0.05
Figure 2. Timing of infusion reactions (IRs). The bars show the incidence of IRs for each number of cetuximab treatments received. One patient with a grade
3 IR was excluded because the time to the onset of IR was unknown.
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MABEL study (15.4%).
Skin disorders were the most frequent ADRs, and the time
to event was different for each disorder similar to previous
reports (12). The occurrence of skin disorders is considered
a predictive factor for the efﬁcacy of EGFR inhibitors (4,13),
and it is important to manage skin disorders by considering
the occurrence time of each symptom to continue the cetuxi-
mab treatment.
The incidence of ILDs in this surveillance (1.2%) was
higher than that in the MABEL study (0.3%) (14). With
other drugs, it has been suggested that the incidence of ILDs
in Japanese patients is higher than that in Caucasian patients
(15,16). ILDs are often followed by serious outcomes includ-
ing death, while no certain tendency in time of onset of
ILDs was observed in this surveillance. Urgent consultation
with a respiratory specialist and the introduction of cortico-
steroid pulse therapy should be considered when observing
suspicious symptoms and/or images of ILDs.
The incidence of cardiotoxicity was low in this surveil-
lance (0.9%), and all patients with cardiotoxicity  grade 3
were treated with irinotecan as combination chemotherapy.
Cardiotoxicity has also been reported following ﬂuorouracil
treatment (17) and it is important to pay close attention
when administering cetuximab in combination with these
drugs.
Figure 3. Cumulative incidence of skin disorders. The lines show the cumulative incidence of each skin disorder over time from the start of administration of
cetuximab using the Kaplan–Meier methods. Skin disorders were divided into seven categories as grouped by symptoms, which is different from the counting
based on the system organ class (SOC) classiﬁcation of Medical Dictionary for Regulatory Activities Terminology (MedDRA).
Figure 4. The incidence of adverse drug reactions (ADRs) with/without combination chemotherapy. The bars show the incidence of ADRs in patients with/
without combination chemotherapy. Combi Cx (2): patients receiving cetuximab alone. Combi Cx (þ): patients receiving cetuximab in combination with
chemotherapy.
292 Surveillance of cetuximab in Japanese MCRCDiarrhoea, leukopenia and neutropenia are frequently
observed ADRs caused by cytotoxic anti-cancer drugs, but
in this surveillance, they were rarely observed with adminis-
tration of cetuximab alone. Based on this ﬁnding, cetuximab
can be used safely in elderly patients and those receiving the
drug as later-line treatment.
Although 93.2% of 2006 patients in this surveillance
were treated in third-line or later treatment, the median
duration of treatment was 15.3 weeks (range, 1–73.9), and
11.1% received long-term treatment .48 weeks, while
that in the CO.17 study, in which cetuximab alone was
administered to patients refractory or intolerant to ﬂuorour-
acil, oxaliplatin and irinotecan, was 8.1 weeks (range, 1–
60) (4). Based on these observations, cetuximab treatment
is considered controllable and clinically effective in prac-
tical use in a later-line setting in Japan.
In addition, higher number of treatments and longer dur-
ation of treatment were observed in the patients with wild
KRAS tumours and those who developed skin disorders.
Treatment duration might be considered as a surrogate of the
efﬁcacy of treatment including cetuximab. Thus, it might in-
dicate that these patients had obtained the clinical beneﬁt
from cetuximab treatment.
KRAS status has been reported to be a predictive factor of
response to cetuximab since 2006 (6), and the indication for
t h eu s eo fc e t u x i m a bw a sc h a n g e dt oKRAS wild-type meta-
static CRC in July 2008 by the European Medicines Agency,
and in September 2009 by the US Food and Drug
Administration. At the beginning of this surveillance, there
was no description regarding KRAS status on the Japanese
package insert for cetuximab, and KRAS testing was not
covered by insurance. Therefore, only 15% (n ¼ 263) of the
patients included in this surveillance had undergone KRAS
testing. It is now recommended that KRAS testing, which has
been covered by insurance since April 2010 in Japan, should
be conducted before the administration of cetuximab.
CONCLUSIONS
We conducted a prospective PMS in Japanese patients re-
ceiving cetuximab for the treatment of metastatic CRC.
There was no notable difference in the proﬁles and incidence
of ADRs compared with previous reports from other coun-
tries. Although .90% of the patients received cetuximab as
third-line or later treatment, the treatment was maintained
with a median duration of 15 weeks. Thus, cetuximab is con-
sidered well tolerated and clinically useful for Japanese
patients.
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